The patents claiming ARN23765, the CFTR corrector discovered by the Task Force for Cystic Fibrosis (TFCF) strategic project, are now back to Istituto Italiano di Tecnologia (IIT, Genoa), Fondazione per la Ricerca sulla Fibrosi Cistica (FFC Ricerca), and Istituto G. Gaslini (Genoa), opening the way to new license opportunities and industrial development.
Sionna Therapeutics, which licensed patent rights applicable to ARN23765 in 2021, has elected to terminate its license to the patents. Under its ongoing agreement with IIT, Sionna Therapeutics retains the right to use certain licensed know-how related to the TFCF project for the development and commercialization of Sionna originated compounds.

The corrector ARN23765 was discovered by the TFCF project, the first strategic project funded by FFC Ricerca in 2014 with the goal of developing new drugs able to correct the CFTR genetic defects that cause cystic fibrosis. Under the license to Sionna Therapeutics, the TFCF team shared all the data generated on ARN23765. Since then, Sionna has discovered a compound representing an improvement over ARN23765, which has good pharmacological potency and favorable drug-like properties and was nominated as a development candidate.